Publication: Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses
Issued Date
2014-01-01
Resource Type
ISSN
23523964
Other identifier(s)
2-s2.0-84921972284
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
EBioMedicine. Vol.1, No.1 (2014), 37-45
Suggested Citation
Susan Zolla-Pazner, Paul T. Edlefsen, Morgane Rolland, Xiang Peng Kong, Allan deCamp, Raphael Gottardo, Constance Williams, Sodsai Tovanabutra, Sandra Sharpe-Cohen, James I. Mullins, Mark S. deSouza, Nicos Karasavvas, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Punnee Pitisuttihumi, Jaranit Kaewkungwal, Robert J. O'Connell, Merlin L. Robb, Nelson L. Michael, Jerome H. Kim, Peter Gilbert Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses. EBioMedicine. Vol.1, No.1 (2014), 37-45. doi:10.1016/j.ebiom.2014.10.022 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/33496
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses
Author(s)
Susan Zolla-Pazner
Paul T. Edlefsen
Morgane Rolland
Xiang Peng Kong
Allan deCamp
Raphael Gottardo
Constance Williams
Sodsai Tovanabutra
Sandra Sharpe-Cohen
James I. Mullins
Mark S. deSouza
Nicos Karasavvas
Sorachai Nitayaphan
Supachai Rerks-Ngarm
Punnee Pitisuttihumi
Jaranit Kaewkungwal
Robert J. O'Connell
Merlin L. Robb
Nelson L. Michael
Jerome H. Kim
Peter Gilbert
Paul T. Edlefsen
Morgane Rolland
Xiang Peng Kong
Allan deCamp
Raphael Gottardo
Constance Williams
Sodsai Tovanabutra
Sandra Sharpe-Cohen
James I. Mullins
Mark S. deSouza
Nicos Karasavvas
Sorachai Nitayaphan
Supachai Rerks-Ngarm
Punnee Pitisuttihumi
Jaranit Kaewkungwal
Robert J. O'Connell
Merlin L. Robb
Nelson L. Michael
Jerome H. Kim
Peter Gilbert
Other Contributor(s)
New York Veterans Affairs Harbor Healthcare System
NYU School of Medicine
Fred Hutchinson Cancer Research Center
Walter Reed Army Institute of Research
University of Washington, Seattle
Thai Red Cross AIDS Research Centre
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
Mahidol University
US Military HIV Research Program
NYU School of Medicine
Fred Hutchinson Cancer Research Center
Walter Reed Army Institute of Research
University of Washington, Seattle
Thai Red Cross AIDS Research Centre
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
Mahidol University
US Military HIV Research Program
Abstract
© 2014 The Authors. To evaluate the role of V3-specific IgG+antibodies (Abs) in the RV144 clinical HIV vaccine trial, which reducedHIV-1 infection by 31.2%, the anti-V3 Ab response was assessed. Vaccinees' V3 Abs were highly cross-reactivewith cyclic V3 peptides (cV3s) from diverse virus subtypes. Sieve analysis of CRF01_AE breakthrough virusesfrom 43 vaccine- and 66 placebo-recipients demonstrated an estimated vaccine efficacy of 85% against viruseswith amino acids mismatching the vaccine at V3 site 317 (p= 0.004) and 52% against virusesmatching the vaccineat V3 site 307 (p = 0.004). This analysis was supported by data showing that vaccinees' plasma Abs wereless reactive with I307when replaced with residues foundmore often in vaccinees' breakthrough viruses. Simultaneously, viruses with mutations at F317were less infectious, possibly due to the contribution of F317to optimalformation of the V3 hydrophobic core. These data suggest that RV144-induced V3-specific Abs imposed immunepressure on infecting viruses and inform efforts to design an HIV vaccine.